UK shareholder meetings calendar - next 7 days
22nd Jan 2026 17:13
| Price | 11.00p on 06-02-2026 at 19:40:05 |
|---|---|
| Change | -1.00p -8.4% |
| Buy | 12.00p |
| Sell | 10.00p |
| Last Trade: | Sell 16,000.00 at 10.90p |
| Day's Volume: | 512,779 |
| Last Close: | 10.90p |
| Open: | 11.90p |
| ISIN: | GB00B02LCQ05 |
| Day's Range | 10.50p - 11.90p |
| 52wk Range: | 5.25p - 12.10p |
| Market Capitalisation: | £669.42m |
| VWAP: | 10.57033p |
| Shares in Issue: | 6.14b |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Allergy Thera. (AGY) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Sell* | 16,000 | 10.90p | Uncrossing Trade |
16:35:05 - 06-Feb-26 |
| Sell* | 12,000 | 10.565p | Ordinary |
15:59:18 - 06-Feb-26 |
| Buy* | 398 | 12.00p | SI Trade |
15:09:21 - 06-Feb-26 |
| Sell* | 124 | 10.00p | SI Trade |
15:09:21 - 06-Feb-26 |
| Buy* | 44 | 12.00p | SI Trade |
15:09:21 - 06-Feb-26 |
| Buy* | 218 | 12.00p | SI Trade |
15:09:21 - 06-Feb-26 |
| Buy* | 50 | 12.00p | SI Trade |
15:09:21 - 06-Feb-26 |
| Sell* | 393 | 10.00p | SI Trade |
15:09:21 - 06-Feb-26 |
| Sell* | 57 | 10.00p | SI Trade |
15:09:21 - 06-Feb-26 |
| Buy* | 1,810 | 11.0444p | Ordinary |
14:02:43 - 06-Feb-26 |
Allergy Thera. (AGY) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 30th Jan 2026 8:22 am | RNS | Chief Strategy Officer and Board appointments |
| 29th Jan 2026 2:13 pm | RNS | Result of Annual General Meeting |
| 28th Jan 2026 4:48 pm | RNS | Grant of Options under Long Term Incentive Scheme |
| 19th Jan 2026 7:00 am | RNS | Half Year Trading Update |
| 6th Jan 2026 7:00 am | RNS | Notice of 2025 Annual General Meeting |
| 29th Dec 2025 1:07 pm | RNS | Results of General Meeting |
| 29th Dec 2025 1:07 pm | RNS | Results of General Meeting |
| 16th Dec 2025 7:00 am | RNS | Grassmuno® marketing authorisation in Germany |
| 12th Dec 2025 7:00 am | RNS | Authority for allotment of New Shares |
| 11th Dec 2025 7:00 am | RNS | Prelim Results and publication of Annual Report |